Terms ending in 2038
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,287,307 | Crystalline Forms of Tenofovir Alafenamide In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,440,928 | Crystalline Forms of Tenofovir Alafenamide In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 12,202,849 | Crystalline Forms of Tenofovir Alafenamide In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 10,442,804 | Compounds for the Treatment of Hepatitis B Virus Infection In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 10,294,234 | HIV Inhibitor Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 10,752,636 | HIV Inhibitor Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,078,208 | HIV Inhibitor Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 12,479,853 | HIV Inhibitor Compounds In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 10,336,762 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US D979,401 | Blister Pack Packaging Blank In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| 32 more term ends in 2038 · Pro | |||||
10 of 42 patents shown. Soonest term end first, then patent number.
Pro members see all 42.
39 of these are in force and held by Gilead Sciences, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.